Identification and evaluation of immunogenic MHC-I and MHC-II binding peptides from Mycobacterium tuberculosis

Comput Biol Med. 2021 Mar:130:104203. doi: 10.1016/j.compbiomed.2020.104203. Epub 2020 Dec 29.

Abstract

Due to several limitations of the only available BCG vaccine, to generate adequate protective immune responses, it is important to develop potent and cost-effective vaccines against tuberculosis (TB). In this study, we have used an immune-informatics approach to identify potential peptide based vaccine targets against TB. The proteome of Mycobacterium tuberculosis (Mtb), the causative agent of TB, was analyzed for secretory or surface localized antigenic proteins as potential vaccine candidates. The T- and B-cell epitopes as well as MHC molecule binding efficiency were identified and mapped in the modelled structures of the selected proteins. Based on antigenicity score and molecular dynamic simulation (MD) studies two peptides namely Pep-9 and Pep-15 were analyzed, modelled and docked with MHC-I and MHC-II structures. Both peptides exhibited no cytotoxicity and were able to induce proinflammatory cytokine secretion in stimulated macrophages. The molecular docking, MD and in-vitro studies of the predicted B and T-cell epitopes of Pep-9 and Pep-15 peptides with the modelled MHC structures exhibited strong binding affinity and antigenic properties, suggesting that the complex is stable, and that these peptides can be considered as a potential candidates for the development of vaccine against TB.

Keywords: Epitope; Peptide; Tuberculosis; Vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epitopes, T-Lymphocyte
  • Histocompatibility Antigens Class II
  • Molecular Docking Simulation
  • Mycobacterium tuberculosis*
  • Peptides

Substances

  • Epitopes, T-Lymphocyte
  • Histocompatibility Antigens Class II
  • Peptides